Compare Amylx Pharmaceuticals Inc (AMLX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Nvidia Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Nvidia Corp trades at $218.06 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 2083× Amylx Pharmaceuticals Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NVDA | |
|---|---|---|
Market Cap | $2.53B | $5.27T |
Sector | Health | Technology |
52-Week High | $24.19 | $235.75 |
52-Week Low | $7.82 | $165.17 |
Enterprise Value | $2.28B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
NVIDIA (NVDA) trades at $217.56, down 2.86% over 24 hours, amid a broader tech sell-off. The stock maintains strong fundamentals with Q1 2026 EPS beating estimates at $1.87 and a net income margin of 62.97%. Technical analysis shows a bullish trend with support at $215 and resistance at $222, while RSI indicates neutral momentum.
Outlook remains positive given robust AI-driven revenue growth and a $325.86 analyst price target, but risks include high valuation multiples and competitive pressures. The stock presents a long-term growth opportunity, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
